Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORTCOM I | SPRT | 3.75% |
| UNISYS CORP | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MOUNTA | GMCR | 3.13% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Specialty chemicals company Rockwood Holdings, Inc. (ROC - Snapshot Report) has announced a roughly 15% hike in its quarterly dividend to 40 cents per share from the prior payout of 35 cents. The increased dividend will be paid on Mar 22, 2013, to stockholders of record as of Mar 7, 2013.
Princeton, NJ-based Rockwood is a premier specialty chemical and advanced materials company. The company reported net sales of nearly $3.5 billion in 2012 and employs roughly 10,200 people worldwide.
A few days ago, the company released its fourth-quarter 2012 results. Profit from continuing operations, as reported, fell to $21.2 million or 26 cents per share in the quarter from $63 million or 79 cents per share a year ago. Adjusted earnings from continuing operations of 45 cents per share missed the Zacks Consensus Estimate of 48 cents.
Revenues came in at $829 million in the quarter, up 1.8% from $814 million recorded in the year-ago quarter, beating Zacks Consensus Estimate of $795 million.
Recently, Rockwood entered into an agreement to acquire Kemira Oyj’s 39% stake in their titanium dioxide (TiO2) joint venture “Sachtleben.” With this buyout, Rockwood will get 100% ownership of the joint venture.
Rockwood expects its Lithium, Surface Treatment and Advanced Ceramics businesses to perform well in the near future. Its Performance Additives segment is expected to gain from any material recovery in the U.S. housing market. However, weak performance is expected in the TiO2 business in the first half of 2013 with improved results expected in the second half anticipating stabilization in pricing and raw material costs.
Rockwood currently maintains a Zacks Rank #3 (Hold).
Other companies in the specialty chemicals space with favorable Zacks Rank are Novozymes A/S (NVZMY), Penford Corporation (PENX - Snapshot Report) and Chemtura Corporation (CHMT - Snapshot Report). While both Novozymes and Penford retain a Zacks Rank #1 (Strong Buy), Chemtura holds a Zacks Rank #2 (Buy).
Get the full Snapshot Report on ROC - FREE
Get the full Snapshot Report on CHMT - FREE
Get the full on NVZMY - FREE
Get the full Snapshot Report on PENX - FREE